UPDATED Jun 25, 2024
Companys with strong funding and high growth potential
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
BOVN.F | SEK 4.70 | 0% | n/a | SEK 2.7b | SEK 12.58 | PS9.2x | E62.0% | n/a | Pharmaceuticals & Biotech | ||
0RV2 | SEK 226.87 | 6.1% | -18.7% | SEK 20.0b | SEK 368.12 | PS79.4x | E50.9% | 0% | Pharmaceuticals & Biotech | ||
SGEN | US$228.74 | 4.5% | 76.5% | US$43.2b | US$228.91 | PS18.8x | E71.8% | n/a | Pharmaceuticals & Biotech | ||
0A8R | US$228.95 | 4.6% | 81.1% | US$43.2b | US$229.12 | PS18.8x | E71.8% | n/a | Pharmaceuticals & Biotech | ||
IMGN | US$31.23 | 6.6% | 617.9% | US$8.4b | US$28.95 | PS29.1x | E45.8% | n/a | Pharmaceuticals & Biotech | ||
IVVD | US$1.21 | -13.6% | 8.0% | US$151.5m | US$9.23 | PB0.8x | E69.8% | n/a | Pharmaceuticals & Biotech | ||
0A8K | US$31.24 | 6.4% | 658.3% | US$8.4b | US$29.16 | PS29.1x | E45.9% | n/a | Pharmaceuticals & Biotech | ||
ARDX | US$6.02 | 1.2% | 79.2% | US$1.5b | US$13.83 | PS8.9x | E60.7% | n/a | Pharmaceuticals & Biotech | ||
BRCT.F | SEK 21.00 | 0% | -30.1% | SEK 20.0b | SEK 34.07 | PS79.4x | E50.9% | 0% | Pharmaceuticals & Biotech | ||
LEGN | US$43.52 | 7.5% | -39.7% | US$7.9b | US$82.50 | PS23.1x | E63.7% | n/a | Pharmaceuticals & Biotech | ||
ISEE | US$39.95 | 0.9% | 236.3% | US$5.5b | US$40.00 | PB11.6x | E59.0% | n/a | Pharmaceuticals & Biotech | ||
CLRB | US$2.70 | 1.1% | 46.7% | US$102.5m | US$15.25 | PB10.7x | E66.9% | n/a | Pharmaceuticals & Biotech | ||
IVBI.Y | HK$19.50 | -1.3% | n/a | HK$61.8b | HK$28.38 | PS9.3x | E50.8% | n/a | Pharmaceuticals & Biotech | ||
MGTX | US$4.21 | -1.4% | -33.6% | US$273.9m | US$21.20 | PS23.8x | E56.1% | n/a | Pharmaceuticals & Biotech | ||
ALDX | US$3.33 | -8.3% | -55.4% | US$195.5m | US$9.25 | PB1.7x | E60.0% | n/a | Pharmaceuticals & Biotech | ||
TVTX | US$7.96 | 12.1% | -49.7% | US$593.0m | US$14.86 | PS3.9x | E67.6% | n/a | Pharmaceuticals & Biotech | ||
SLNO | US$38.94 | -7.1% | 890.8% | US$1.5b | US$67.29 | PB9.9x | E65.2% | n/a | Pharmaceuticals & Biotech | ||
SPRY | US$7.65 | -5.3% | 17.7% | US$798.4m | US$19.00 | PS74124.9x | E58.7% | n/a | Pharmaceuticals & Biotech | ||
MDGL | US$280.04 | 1.5% | 37.4% | US$6.1b | US$365.07 | PB7x | E64.3% | n/a | Pharmaceuticals & Biotech | ||
RCEL | US$7.94 | -1.0% | -49.3% | US$209.2m | US$23.22 | PS4.1x | E61.3% | n/a | Pharmaceuticals & Biotech | ||
ACAD | US$15.60 | 4.9% | -35.6% | US$2.6b | US$27.16 | PS3.2x | E41.8% | n/a | Pharmaceuticals & Biotech | ||
CSPH.F | HK$0.12 | 0% | n/a | HK$1.4b | n/a | PS2.8x | E98.1% | n/a | Pharmaceuticals & Biotech | ||
MSB | AU$0.98 | -9.7% | -9.7% | AU$1.1b | AU$1.10 | PS100x | E56.7% | n/a | Pharmaceuticals & Biotech | ||
0JDK | US$8.30 | 5.4% | 11.7% | US$2.4b | US$25.29 | PS1241.9x | E64.5% | n/a | Pharmaceuticals & Biotech |